Opinion|Videos|February 5, 2025
Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC
Panelists discuss how trastuzumab deruxtecan (T-DXd) demonstrated favorable patient-reported outcomes and quality of life measures in HER2-low hormone receptor-positive metastatic breast cancer patients in DESTINY-Breast06, suggesting it could be a well-tolerated therapeutic option that maintains patients' daily functioning while providing clinical benefit.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What insights do the patient-reported outcomes and quality of life data from the DESTINY-Breast06 trial show, and how might these findings inform patient care?
Advertisement
Related to this article
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
5